Information Resources on the Care and Welfare of Cats
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Conservation of the Wildcat (Felis Silvestris) in Scotland: Review of the Conservation Status and Assessment of Conservation Activities
Conservation of the wildcat (Felis silvestris) in Scotland: Review of the conservation status and assessment of conservation activities Urs Breitenmoser, Tabea Lanz and Christine Breitenmoser-Würsten February 2019 Wildcat in Scotland – Review of Conservation Status and Activities 2 Cover photo: Wildcat (Felis silvestris) male meets domestic cat female, © L. Geslin. In spring 2018, the Scottish Wildcat Conservation Action Plan Steering Group commissioned the IUCN SSC Cat Specialist Group to review the conservation status of the wildcat in Scotland and the implementation of conservation activities so far. The review was done based on the scientific literature and available reports. The designation of the geographical entities in this report, and the representation of the material, do not imply the expression of any opinion whatsoever on the part of the IUCN concerning the legal status of any country, territory, or area, or its authorities, or concerning the delimitation of its frontiers or boundaries. The SWCAP Steering Group contact point is Martin Gaywood ([email protected]). Wildcat in Scotland – Review of Conservation Status and Activities 3 List of Content Abbreviations and Acronyms 4 Summary 5 1. Introduction 7 2. History and present status of the wildcat in Scotland – an overview 2.1. History of the wildcat in Great Britain 8 2.2. Present status of the wildcat in Scotland 10 2.3. Threats 13 2.4. Legal status and listing 16 2.5. Characteristics of the Scottish Wildcat 17 2.6. Phylogenetic and taxonomic characteristics 20 3. Recent conservation initiatives and projects 3.1. Conservation planning and initial projects 24 3.2. Scottish Wildcat Action 28 3.3. -
Submaxillary Gland and the A2a- and A2b-Adrenoceptor Subtypes 1Anton D
Br. J. Pharmacol. (1989), 98, 890-897 Differences between the cx2-adrenoceptor in rat submaxillary gland and the a2A- and a2B-adrenoceptor subtypes 1Anton D. Michel, Dana N. Lodry & Roger L. Whiting Institute of Pharmacology, Syntex Research, 3401 Hillview Avenue, Palo Alto, CA, 94303, U.S.A. 1 The a2-adrenoceptors of rat submaxillary gland, labelled with [3H]-rauwolscine, were character- ized by use of a range of subtype selective ligands and were compared to rabbit spleen a2A-adrenoceptors and rat kidney a2B-adrenoceptors. 2 In rat submaxillary gland, [3H]-rauwolscine labelled an apparently homogeneous population of binding sites with relatively low affinity (Kd= 11.65 nM) compared to the affinity in rat kidney (Kd = 2.18 nM) and rabbit spleen (Kd = 4.64 nM). 3 In competition studies using 16 ligands the a2-adrenoceptors in rat submaxillary gland appeared to differ from both the x2A-adrenoceptor of rabbit spleen (r = 0.62) and also the a2B-adrenoceptor of rat kidney (r = 0.28). 4 The affinity data obtained with benoxathian, imiloxan and WB 4101 indicated the presence of an a2B-adrenoceptor in rat submaxillary gland. However, data for chlorpromazine, oxymetazoline, spiroxatrine and xylometazoline indicated that submaxillary gland a2-adrenoceptors were of the a2A subtype. The affinity estimate for prazosin in rat submaxillary gland was intermediate between its affinity at the ae2A- and a2B-adrenoceptors while affinity estimates for idazoxan and phentolamine in rat submaxillary gland were greater than those obtained at either the c2A- or x2B-adrenoceptor. 5 These data indicate that rat submaxillary gland a2-adrenoceptors differ from the CX2A- and a2B-adrenoceptors found in rabbit spleen and rat kidney, respectively. -
The Role of Acetylcholine in Cocaine Addiction
Neuropsychopharmacology (2008) 33, 1779–1797 & 2008 Nature Publishing Group All rights reserved 0893-133X/08 $30.00 www.neuropsychopharmacology.org Perspective The Role of Acetylcholine in Cocaine Addiction ,1 1,2 Mark J Williams* and Bryon Adinoff 1Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA; 2Mental Health Service, VA North Texas Health Care System, Dallas, TX, USA Central nervous system cholinergic neurons arise from several discrete sources, project to multiple brain regions, and exert specific effects on reward, learning, and memory. These processes are critical for the development and persistence of addictive disorders. Although other neurotransmitters, including dopamine, glutamate, and serotonin, have been the primary focus of drug research to date, a growing preclinical literature reveals a critical role of acetylcholine (ACh) in the experience and progression of drug use. This review will present and integrate the findings regarding the role of ACh in drug dependence, with a primary focus on cocaine and the muscarinic ACh system. Mesostriatal ACh appears to mediate reinforcement through its effect on reward, satiation, and aversion, and chronic cocaine administration produces neuroadaptive changes in the striatum. ACh is further involved in the acquisition of conditional associations that underlie cocaine self-administration and context-dependent sensitization, the acquisition of associations in conditioned learning, and drug procurement through its effects on arousal and attention. Long-term cocaine use may induce neuronal alterations in the brain that affect the ACh system and impair executive function, possibly contributing to the disruptions in decision making that characterize this population. These primarily preclinical studies suggest that ACh exerts a myriad of effects on the addictive process and that persistent changes to the ACh system following chronic drug use may exacerbate the risk of relapse during recovery. -
Effects of Prophylactic Ketamine and Pethidine to Control Postanesthetic Shivering: a Comparative Study
Biomedical Research and Therapy, 5(12):2898-2903 Original Research Effects of prophylactic ketamine and pethidine to control postanesthetic shivering: A comparative study Masoum Khoshfetrat1, Ali Rosom Jalali2, Gholamreza Komeili3, Aliakbar Keykha4;∗ ABSTRACT Background: Shivering is an undesirable complication following general anesthesia and spinal anesthesia, whose early control can reduce postoperative metabolic and respiratory complications. Therefore, this study aims to compare the effects of prophylactic injection of ketamine and pethi- dine on postoperative shivering.Methods: This double-blind clinical trial was performed on 105 patients with short-term orthopedic and ENT surgery. The patients were randomly divided into three groups; 20 minutes before the end of the surgery, 0.4 mg/kg of pethidine was injected to the first group, 0.5 mg/kg of ketamine was injected to the second group, and normal saline was injected to the third group. After the surgery, the tympanic membrane temperature was measured at 0, 10, 20, and 30 minutes. The shivering was also measured by a four-point grading from zero (no shiv- ering) to four (severe shivering). Data were analyzed by one-way ANOVA, Kruskal Wallis, Chi-square 1Doctor of Medicine (MD), Fellow of and Pearson correlation. Results: The mean age of patients was 35.811.45 years in the ketamine Critical Care Medicine (FCCM), group, 34.811.64 years in the normal saline group, and 33.1110.5 years in the pethidine group. Department of Anesthesiology and The one-way ANOVA showed no significant difference in the mean age between the three groups Critical Care, Khatam-Al-Anbiya (P=0.645). -
Viewed the Existence of Multiple Muscarinic CNS Penetration May Occur When the Blood-Brain Barrier Receptors in the Mammalian Myocardium and Have Is Compromised
BMC Pharmacology BioMed Central Research article Open Access In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine G Howell III†1, L West†1, C Jenkins2, B Lineberry1, D Yokum1 and R Rockhold*1 Address: 1Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA and 2Tougaloo College, Tougaloo, MS, USA Email: G Howell - [email protected]; L West - [email protected]; C Jenkins - [email protected]; B Lineberry - [email protected]; D Yokum - [email protected]; R Rockhold* - [email protected] * Corresponding author †Equal contributors Published: 18 August 2005 Received: 06 October 2004 Accepted: 18 August 2005 BMC Pharmacology 2005, 5:13 doi:10.1186/1471-2210-5-13 This article is available from: http://www.biomedcentral.com/1471-2210/5/13 © 2005 Howell et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Muscarinic receptor mediated adverse effects, such as sedation and xerostomia, significantly hinder the therapeutic usefulness of first generation antihistamines. Therefore, second and third generation antihistamines which effectively antagonize the H1 receptor without significant affinity for muscarinic receptors have been developed. However, both in vitro and in vivo experimentation indicates that the third generation antihistamine, desloratadine, antagonizes muscarinic receptors. To fully examine the in vivo antimuscarinic efficacy of desloratadine, two murine and two rat models were utilized. The murine models sought to determine the efficacy of desloratadine to antagonize muscarinic agonist induced salivation, lacrimation, and tremor. -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
Publications for Julia Beatty 2021 2020 2019
Publications for Julia Beatty 2021 <a href="http://dx.doi.org/10.1089/vbz.2019.2520">[More Mazeau, L., Wylie, C., Boland, L., Beatty, J. (2021). A shift Information]</a> towards early‑age desexing of cats under veterinary care in Australia. Scientific Reports, 11(1), 1-9. <a 2019 href="http://dx.doi.org/10.1038/s41598-020-79513-6">[More Pesavento, P., Jackson, K., Scase, T., Tse, T., Hampson, B., Information]</a> Munday, J., Barrs, V., Beatty, J. (2019). A Novel Hepadnavirus Kay, A., Boland, L., Kidd, S., Beatty, J., Talbot, J., Barrs, V. is Associated with Chronic Hepatitis and Hepatocellular (2021). Complete clinical response to combined antifungal Carcinoma in Cats. Viruses, 11(10), 1-8. <a therapy in two cats with invasive fungal rhinosinusitis caused href="http://dx.doi.org/10.3390/v11100969">[More by cryptic Aspergillus species in section Fumigati. Medical Information]</a> Mycology Case Reports, 34, 13-17. <a Whitney, J., Haase, B., Beatty, J., Barrs, V. (2019). Breed- href="http://dx.doi.org/10.1016/j.mmcr.2021.08.005">[More specific variations in the coding region of toll-like receptor 4 in Information]</a> the domestic cat. Veterinary Immunology and Sacrist�n, I., Acu�a, F., Aguilar, E., Garc�a, S., Jos� Immunopathology, 209, 61-69. <a L�pez, M., Cabello, J., Hidalgo-Hermoso, E., Sanderson, J., href="http://dx.doi.org/10.1016/j.vetimm.2019.02.009">[More Terio, K., Barrs, V., Beatty, J., et al (2021). Cross-species Information]</a> transmission of retroviruses among domestic and wild felids in Van Brussel, K., Carrai, M., Lin, C., Kelman, M., Setyo, L., human-occupied landscapes in Chile. -
Tesis Beatriz Unzeta.PDF
DEPARTAMENTO DE MEDICINA, CIRUGÍA Y ANATOMÍA VETERINARIA FACULTAD DE VETERINARIA UNIVERSIDAD DE LEÓN PREVALENCIA Y CARACTERIZACIÓN CLÍNICO-LESIONAL DE LOS PRINCIPALES PROCESOS INFECCIOSOS DE ETIOLOGÍA VÍRICA QUE AFECTAN A LAS COLONIAS DE GATOS CALLEJEROS EN MADRID CAPITAL PREVALENCE AND CLINICO-PATHOLOGICAL CHARACTERIZATION OF THE MAIN VIRAL INFECTIONS AFFECTING STREET CAT COLONIES IN MADRID Beatriz Unzeta Conde León, 2015 MEMORIA PARA OPTAR AL GRADO DE DOCTOR EN VETERINARIA POR LA UNIVERSIDAD DE LEÓN TESIS DOCTORAL BEATRIZ UNZETA CONDE FACULTAD DE VETERINARIA DE LA UNIVERSIDAD DE LEON AGRADECIMIENTOS 1 TESIS DOCTORAL BEATRIZ UNZETA CONDE FACULTAD DE VETERINARIA DE LA UNIVERSIDAD DE LEON Hace casi 7 años comencé con este proyecto de Tesis Doctoral que supuso para mí un gran reto. En este tiempo ha habido momentos buenos y malos, unos más fáciles y otros más complicados en los personal y en lo laboral y en ocasiones era difícil atisbar el final del camino, pero es ahora cuando todo culmina, cuando echo la vista atrás y sólo puedo sentirme agradecida a la vida y a todos los que me han rodeado en este tiempo. Gracias por hacerme crecer, porque cada vez que me he caído me han ayudado a levantarme, porque cuando el paso era ligero también me han acompañado disfrutando de esos momentos. Ahora que finaliza y hago un resumen de estos siete últimos años me doy cuenta de lo que he crecido como veterinaria clínica junto con este proyecto. Mi amor y afición por los gatos surgió ya desde que me licencié en Veterinaria y me uní al GEMFE, grupo de especialidad en Medicina Felina de AVEPA, formándome con especial interés en la medicina felina. -
4 Supplementary File
Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation. -
WO 2012/068516 A2 24 May 20 12 (24.05.2012) W P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/068516 A2 24 May 20 12 (24.05.2012) W P O P C T (51) International Patent Classification: (72) Inventors; and A61K 31/352 (2006.01) A61P 25/24 (2006.01) (75) Inventors/Applicants (for US only): LETENDRE, Peter A61K 9/48 (2006.01) A61P 25/22 (2006.01) [US/US]; 2389 Indian Peaks Trail, Lafayette, Colorado A61K 9/20 (2006.01) A61P 25/00 (2006.01) 80026 (US). CARLEY, David [US/US]; 2457 Pioneer Rd., Evanston, Illinois 60201 (US). (21) International Application Number: PCT/US201 1/061490 (74) Agents: FEDDE, Kenton et al; 18325 AUenton Woods Ct, Wildwood, Missouri 63069 (US). (22) International Filing Date: 18 November 201 1 (18.1 1.201 1) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Language: English Filing AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (30) Priority Data: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, 61/415,33 1 18 November 2010 (18. 11.2010) US KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (71) Applicant (for all designated States except US): PIER MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PHARMACEUTICALS [US/US]; 901 Front St., Suite OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 201, Louisville, Colorado 80027 (US). -
Immune-Inflammatory Concept of the Pathogenesis of Chronic Heart Failure in Dogs with Dilated Cardiomyopathy
Veterinary World, EISSN: 2231-0916 RESEARCH ARTICLE Available at www.veterinaryworld.org/Vol.12/September-2019/21.pdf Open Access Immune-inflammatory concept of the pathogenesis of chronic heart failure in dogs with dilated cardiomyopathy Yu Vatnikov1, A. Rudenko2, P. Rudenko3, Ev Kulikov1, A. Karamyan1, V. Lutsay2, I. Medvedev4, V. Byakhova1, E. Krotova1 and M. Molvhanova1 1. Department of Veterinary Medicine, Peoples’ Friendship University of Russia (RUDN University), Moscow 117198, Russia; 2. Department of Veterinary Medicine, Moscow State University of Food Production, Moscow 125080, Russia; 3. Laboratory of Biological Experiments, Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Pushchino 117997, Russia; 4. Department of Adaptive Physical Culture and Recreation, Russian State Social University, Moscow 129226, Russia. Corresponding author: V. Byakhova, e-mail: [email protected] Co-authors: YV: [email protected], AR: [email protected], PR: pavelrudenko76@yandex. ru, EvK: [email protected], AK: [email protected], VL: [email protected], IM: [email protected], EK: [email protected], MM: [email protected] Received: 17-02-2019, Accepted: 07-08-2019, Published online: 28-09-2019 doi: 10.14202/vetworld.2019.1491-1498 How to cite this article: Vatnikov Y, Rudenko A, Rudenko P, Kulikov E, Karamyan A, Lutsay V, Medvedev I, Byakhova V, Krotova E, Molvhanova M (2019) Immune-inflammatory concept of the pathogenesis of chronic heart failure in dogs with dilated cardiomyopathy, Veterinary World, 12(9): 1491-1498. Abstract Background: Dilated cardiomyopathy is common in dogs. This form of cardiomyopathy is the main cause of death due to heart disease in dogs. -
D OCELOT CLUB 1454 Fleetwood Drive E
CONTENTS: A11 About Hybrids ............ Page 3 N.J.'s Exotic Law ............Page 6 Election '79 .............. Page 7 Nefertiti ................ Page 8 It's in the Stars ............Page 9 Other Folks ............... Page 10 Believe it or Not ............ Page 11 On Vitamins ............... Page 12 LONG ISLAND OCELOT CLUB 1454 Fleetwood Drive E . 23. Number 2 I Mobile. Alabama 36605 1 March . April 1979 1 D OCELOT CLUB Branch Representatives A.C.E.C. - Bob Smith, President, P.O. Box 26G, Los Angeles, CA 90026 (213) 621-4635 CANADA - Terry Foreman, Coordinator, R.R. *12, Dawson Rd., Thunder Bay, Ontario Canada P7B 5E3 CASCADE - Shelley Starns, 16635 Longmire Rd. S.E., Yelm, WA 98597 (206) 894-2684 L.I.O.C. OF CALIFORNIA - Lora Vigne, 22 Isis St., San Francisco, CA 94102 (415) 552-3748 FLORIDA - Ken Hatfield (Acting President) 1991 S.W. 136 Ave., Davie, Florida 33325 (305) 472-7276 GREATER NEW YORK - Arthur Human, 32 Lockwood Ave., Norwalk, CT 06851 (203) 866-0484 PACIFIC NORTHWEST - Gayle Schaecher, 10715 S.E. Orient Dr., Boring, OR 97009 (503) 633-4673 SOUTHWESTERN - Rebecca Morgan, President, P.O. LONG ISLAND OCELOT CLUB Box 144, Carrollton, TX 75006 (214) 241-6440 NEWSLETTER EXOTIC CATSIGEORGIA - Cat Klass, President, 4704 Brownsville Rd., Powder Springs, GA 30073 (404) 942- 3809 Published Si-monthly by Long Island Ocelot Club '454 Fleetwood OREGON EDUCATIONAL EXOTIC FELINE CLUB - Drive East Mobile Alabama 36605 The Long Island Ocelot Club is a non-profit non-commercial club international n membership, Barbara Wilton, 7800- S.E. Luther Rd., Portland. OR devoted to the welfare of ocelots and all other exot~efelines 97206 (503) 774-1657 Reproduction of the material in this Newsletter may not be made without written permission of the authors andlor the ~opyrightowner LIOC LIOC Officers PLEASE KEN HATFIELD, PRESIDENT, 1991 S.W.